LIVING CURES

LIVING CURES

LIVING CURES

[Re]engineering evolution into Living Cures platform for novel immunotherapies

[Re]engineering evolution into Living Cures platform for novel immunotherapies

[Re]engineering evolution into Living Cures platform for novel immunotherapies

FOUNDATIONAL TECHNOLOGY

Prokarium's Foundational technology leverages inherent anti-tumor mechanisms of a proprietary strain of bacteria (ZH9) as a microbial immunotherapy platform

• Naturally tumor targeting and oncolytic• Overcomes the suppressive tumor microenvironment• Targets multiple pathways to elicit strong anti-tumor immunity• Extensive opportunities to deliver diverse cargo

Proprietary ZH9 Chassis Strain

FOUNDATIONAL TECHNOLOGY

Prokarium's Foundational technology leverages inherent anti-tumor mechanisms of a proprietary strain of bacteria (ZH9) as a microbial immunotherapy platform

• Naturally tumor targeting and oncolytic• Overcomes the suppressive tumor microenvironment• Targets multiple pathways to elicit strong anti-tumor immunity• Extensive opportunities to deliver diverse cargo

Proprietary ZH9 Chassis Strain

MARKET
MARKET
APPLICATIONS
APPLICATIONS
ABOUT US

TEAM

BOARD OF DIRECTORS

ADVISORS

Ibs Mahmood
CEO
Livija Deban, PhD
CSO
Dara Henry, PhD
COO
Josi Holz, MD, PhD
CMO
Julia Jones, FCA
CFO
Nick Glanville, PhD
VP of Research

TEAM

BOARD OF DIRECTORS

ADVISORS

Ibs Mahmood
CEO
Livija Deban, PhD
CSO
Dara Henry, PhD
COO
Josi Holz, MD, PhD
CMO
Julia Jones, FCA
CFO
Nick Glanville, PhD
VP of Research
PIPELINE
Indication
Discovery
Discovery
Preclinical
Preclinical
IND-Enabling
IND-Enabling
Phase I

ZH9 - Bladder cancer Non-muscle invasive

Phase I initiated in US

Read More

Indication

ZH9 - Bladder cancer Non-muscle invasive

Phase I initiated in US

Read More

ZH9 - Bladder cancer Muscle invasive

Combination with checkpoint inhibitors

Read More

Indication

ZH9 - Bladder cancer Muscle invasive

Combination with checkpoint inhibitors

Read More

IO Prime

First-in-class oral immune fitness agent ready to enter the clinic

Read More

Indication

IO Prime

First-in-class oral immune fitness agent ready to enter the clinic

Read More

Living Cures Platform

Discovery cargo-delivery IO platform

Read More

Indication

Living Cures Platform

Discovery cargo-delivery IO platform

Read More

NEWS

18 May 2026

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy

LONDON, UK--(BUSINESS WIRE)--Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting.

Read More

16 February 2026

Prokarium Announces Upcoming Oral Presentations of Interim Clinical Data at the EAU and AUA 2026 Annual Meetings

London, UK - 16 February 2026 - Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment...

Read More

11 November 2025

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK - November 11, 2025 — Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Read More

1 November 2024

Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...

Read More

All News

NEWS

18 May 2026

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy

LONDON, UK--(BUSINESS WIRE)--Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting.

Read More

16 February 2026

Prokarium Announces Upcoming Oral Presentations of Interim Clinical Data at the EAU and AUA 2026 Annual Meetings

London, UK - 16 February 2026 - Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment...

Read More

11 November 2025

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK - November 11, 2025 — Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Read More

All News

CAREERS

Contact

Contact

Contact

London Bioscience Innovation Centre,
2 Royal College St,
NW1 0NH, London, UK

London Bioscience Innovation Centre,
2 Royal College St,
NW1 0NH, London, UK

prokarium

prokarium

Design the future with us

Design the future with us

Design the future with us

CONTACT US

Privacy policy

Cookie policy

Prokarium 2026 © All Rights Reserved

Privacy policy

Cookie policy

Prokarium 2026 © All Rights Reserved

Privacy policy

Cookie policy

Prokarium 2026 © All Rights Reserved